Sonia Vallet

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

Mariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima et al. · Blood · 2009 · 395 citations · Full text

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

Siddhartha Mukherjee, Noopur Raje, Jesse Schoonmaker et al. · Journal of Clinical Investigation · 2008 · 240 citations · Full text

Progenitor Cells, Tissue Engineering, Sclerostin +21

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

Sonia Vallet, Siddhartha Mukherjee, Nileshwari Vaghela et al. · Proceedings of the National Academy of Sciences · 2010 · 232 citations · Full text

Inflammation, Bone Marrow Plasma, Sclerostin +15

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

Yutaka Okawa, Teru Hideshima, Paul M. Steed et al. · Blood · 2008 · 208 citations · Full text

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

Iris Breitkreutz, Marc S. Raab, Sonia Vallet et al. · Leukemia · 2008 · 208 citations

Hematological Malignancy, Bone-remodeling Markers, Medicine +8